Milestone Pharmaceuticals (MIST) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Milestone Pharmaceuticals is gearing up for the potential FDA approval of its CARDAMYST nasal spray for PSVT, with a decision expected by March 2025. The company’s partner, Corxel, reported positive Phase 3 trial results in China, showing significant efficacy in converting PSVT to sinus rhythm. Milestone is actively preparing for a commercial launch and expanding its clinical trials to improve patient care.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.